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Abstract 46 
 47 
Many children with cancer in low- and middle-income countries are treated in hospitals lacking key 48 
infrastructure, including diagnostic capabilities, imaging modalities, treatment components, supportive 49 
care, and personnel. Childhood cancer treatment regimens adapted to local conditions provide an 50 
opportunity to cure as many children as possible with the available resources, while working to improve 51 
services and supportive care. This paper from the Adapted Treatment Regimens Working Group of the 52 
Pediatric Oncology in Developing Countries committee of the International Society of Pediatric Oncology  53 
outlines the design, development, implementation, and evaluation of adapted regimens and specifies 54 
levels of services needed to deliver them.   55 
Introduction 56 
 57 
Need for adapted regimens for use in low- and middle-income countries (LMIC) 58 
Many pediatric cancer units (PCUs) in low- and middle-income countries (LMIC) treat children 59 
with cancer, but lack the infrastructure available to PCUs in high-income countries (HIC). Treatment 60 
using standardized regimens or protocols has led to unprecedented improvements in survival of children 61 
with cancer, but most published regimens are based on therapies developed and delivered in HIC. 62 
Treatment outcomes with these regimens differ in PCUs that treat different patient populations and lack a 63 
full complement of diagnostic facilities, imaging modalities, treatment components, and supportive care.1 64 
Accordingly, treatment risks and benefits may differ substantially between LMIC and HIC.  65 
For example, the Total XI protocol for childhood acute lymphoblastic leukemia (ALL) achieved a 66 
72% event-free survival (EFS) in the United States, but when implemented in Recife, Brazil, the EFS was 67 
32%.2,3 The same regimen was used in El Salvador with adaptations designed to reduce toxicity, including 68 
a 3-drug induction without anthracyclines.4 This approach increased 4-year EFS from less than 10% to 69 
48%. However, despite these adaptations, the rate of toxic death was 12.4% during remission induction 70 
therapy and another 4.6% in remission. This emphasizes the need to not only adapt treatment for LMIC, 71 
but also to carefully evaluate the results of adapted regimens to identify opportunities for further 72 
improvement.5  73 
The first adapted regimens developed were called “graduated intensity regimens,” a term replaced 74 
by “adapted treatment regimens” because the necessary adaptations often do not involve changes in 75 
chemotherapy intensity, but also incorporate use of distinct methods of staging, risk stratification, local 76 
control, and supportive care.6 For example, the retinoblastoma guidelines applied this adaptation process 77 
to outline treatment based on availability of specific ophthalmologic interventions.7 Similarly, additional 78 
chemotherapy was used for Wilms tumor and Hodgkin lymphoma when radiation therapy is 79 
unavailable.8,9 Adaptations may include major changes in therapy, such as addition of chemotherapy and 80 
omission of radiation therapy in Wilms tumor, but could also include relatively minor alterations, such as 81 
omission of 2 doses of doxorubicin from acute lymphoblastic leukemia remission induction therapy or 82 
use of prophylactic antibiotics when the risk/benefit ratio differs in LMIC and HIC. 83 
It might be tempting to defer childhood cancer treatment in settings with suboptimal 84 
infrastructure, but this would be unwise, since most children have no option for transfer to a more 85 
advanced PCU, and many are curable even in settings with limited resources. For example, Burkitt 86 
lymphoma in African PCUs has been successfully treated with reduced-intensity regimens, despite very 87 
limited supportive care and related infrastructure.10-12 Indeed, treatment with a high-intensity regimen 88 
when supportive care is inadequate can lead to paradoxically lower EFS by increasing toxic death more 89 
than it decreases relapse.13-16 Cure rates can rise quickly with focus on preventing treatment abandonment, 90 
reducing toxic death, and adapting the diagnostic strategy, risk stratification algorithm, and treatment 91 
regimen to the local situation.4 In Recife, Brazil, the cure rates for childhood ALL increased from 32% to 92 
over 65% using adapted regimens accompanied by rigorous programs to prevent treatment abandonment 93 
and reduce toxic death.3,17 Curing the curable is ethically mandatory and highly cost-effective even in 94 
LMIC.18-20 95 
 96 
Obstacles to adapting treatment regimens 97 
Obstacles to adapting treatment regimens to local conditions have included an unwillingness to 98 
deviate from published regimens used in HIC due to provider preferences, cultural or historical reasons, 99 
misperception that ‘more is better,’ lack of published evidence about adapted regimens, insufficient local 100 
data on which to base rational adaptations (due to lack of hospital-based registries and routine outcome 101 
evaluation of locally treated patients), perceived ethical concerns about using a less intense regimen, and 102 
lack of time and expertise by LMIC physicians to adapt each regimen to local conditions. In some cases, 103 
physicians practicing in LMIC care for 10 times more patients than their counterparts in HIC. This makes 104 
it very challenging for them to engage in activities other than direct patient care, even if those activities 105 
might ultimately improve survival in their PCU. Furthermore, conditions in PCUs vary greatly, even 106 
within the same country. While there is general agreement that patients should be treated at the PCU that 107 
offers the highest chance of cure, many LMIC have heterogeneous levels of care at various centers 108 
combined with complex health systems that may mandate treatment at a specific PCU based on insurance 109 
coverage and other factors unrelated to expertise. 110 
 111 
Development and implementation of adapted treatment regimens 112 
Several strategies have been employed to overcome the aforementioned obstacles (Table 1). 113 
Many clinicians have devised strategies to try to cure as many patients as possible despite the lack of key 114 
infrastructure at their center. For example, treatment of Hodgkin lymphoma and Wilms tumor without 115 
radiation therapy was first considered in PCUs without access to radiation therapy, and use of reduced 116 
doses of high-dose methotrexate in ALL and non-Hodgkin lymphoma regimens has been studied 117 
extensively in LMIC.9,21-24 In fact, these and other innovative strategies now used in HIC to minimize 118 
toxicity and optimize long-term outcomes were pioneered in LMIC to address conditions that made the 119 
HIC regimen impractical in the local setting, including retinoblastoma staging, treatment of osteosarcoma 120 
without high-dose methotrexate, and others.25,26 121 
To develop and disseminate adapted treatment strategies, the Pediatric Oncology in Developing 122 
Countries (PODC) Committee of the International Society of Pediatric Oncology (SIOP) established the 123 
Adapted Treatment Regimens Working Group, charged with providing such regimens for use in LMIC.30 124 
The volunteer leaders serve for 3-year terms and volunteer members carry out the projects. Meetings are 125 
conducted online via www.Cure4Kids.org and members listed on the SIOP web site (www.siop-126 
online.org). To date, working group members have published adapted regimens for 7 cancers along with 2 127 
supportive care manuscripts.5-7,27-34 The published adapted regimens were developed with broad input 128 
from clinicians in multiple disciplines, and experts from LMIC and HIC, and have been improved during 129 
extensive review by peers from the global oncology community. Where possible, recommendations have 130 
been evidence-based, but when published evidence to guide regimen selection was not available, as is 131 
often the case in the most resource-limited settings, expert opinion was used. Four of these guidelines 132 
(Wilms tumor, Kaposi sarcoma, Burkitt lymphoma, and supportive care35-37) were designed for settings in 133 
low-income countries where only the minimal requirements for treatment with curative intent are 134 
available (defined as setting 1, see Table 2). However, for some cancers, definition of an overall level of 135 
care was insufficient to select the best treatment regimen, because they depend on access to a particular 136 
component of care, such as neurosurgery for brain cancers or radiation therapy for unresectable sarcomas. 137 
Therefore, a framework based on specific service lines was required to guide clinicians to the best 138 
treatment, and to highlight the need for certain service lines to treat specific cancers. This paper provides 139 
such a framework and suggests components for each adapted regimen to make it maximally useful and 140 
applicable.  141 
 142 
Choosing the optimal therapy depends on the setting 143 
The “optimal” therapy in LMIC is not necessarily that used in HIC, but that which provides each 144 
child with the highest probability of cure in the given setting at the time of diagnosis. Of necessity, in 145 
LMIC the optimal therapy will change over time, with improvements in diagnostic accuracy, surgical 146 
expertise, improved access to supportive care and treatments such as radiation therapy or new drugs, 147 
implementation of treatment abandonment prevention programs, and as improved regimens are identified 148 
by research in HIC and LMIC. If the relapse rate with a given therapy is excessive, then the treatment 149 
may need intensification; however, if toxic death rates are too high, de-intensification may save more 150 
lives, pending improvements in supportive care. Therefore, constant evaluation of the regimens is 151 
imperative. 152 
Selection of the optimal regimen for patients treated in a specific setting does not preclude 153 
making every effort to improve the environment of care. Explicit identification of the care that can be 154 
safely delivered may help prioritize quality improvement efforts. In general, priorities to improve survival 155 
rates include investments in core services for appropriate diagnosis and management: pathology and 156 
diagnostic imaging; nursing and access to essential medicines; prevention of toxic death by hand hygiene 157 
programs and rapid access to effective antibiotics; prevention of abandonment by provision of subsidized 158 
transportation, local housing, and food baskets; and family education and support programs. However, 159 
after these essentials are in place, whether efforts should be put toward early diagnosis of retinoblastoma, 160 
local control for sarcoma patients, development of neurosurgical expertise for brain tumors, improved 161 
diagnosis and risk stratification systems, or other important aspects of pediatric cancer care depends on 162 
many factors. Of course, the initial focus should always be on curing the most curable patients. While the 163 
choice of focus and resource allocation will differ in different centers, prioritization can be evidence-164 
based once incidence and outcome data are available for the various cancer types treated with adapted 165 
regimens and explicit evaluation criteria are formulated for each.   For example, a PCU in which 20% of 166 
children with ALL die of toxicity during the first 3 months of therapy would appropriately select the 167 
Level 1 regimen for ALL, but as supportive care improves and toxic death decreases to 3%, excess 168 
relapse with a low-intensity treatment regimen may merit stepping up to the Level 2 regimen (Table 2).5 169 
However, if toxic death occurs in 5 of the next 25 patients treated with the Level 2 regimen, the stopping 170 
rule would be triggered and clinicians would know to step down to the Level 1 regimen and redouble 171 
efforts to improve supportive care. Decisions about the optimal regimen for a PCU would ideally fit 172 
within the context of regional and international disease-specific networks, such as the Global 173 
Neuroblastoma Network where peers and colleagues provide advice about treatment regimens and 174 
specific patients and implemented in the context of regional collaboration networks such as those listed in 175 
Table 1.33 176 
 177 
Adapted treatment regimens, research, and individualized care 178 
 179 
Adapted regimens for each pediatric cancer unit 180 
Adapted regimens apply to groups of patients, and are based on the axiom that standardized care and 181 
following a specific regimen improves results for pediatric cancer patients, who require complex, 182 
prolonged treatments, often involving many disciplines. Minimizing variation in the regimen used for 183 
patients with the same disease allows oncologists, pediatricians, nurses, pharmacists, and other caregivers 184 
to develop expertise and a deep understanding of the regimen’s, expected toxicities while improving 185 
communication among team members.  186 
 187 
Adapted regimens and research 188 
Adapted regimens are not research protocols per se; rather, they represent efforts to improve care in each 189 
PCU for each disease. Adapted regimens are best applied in conjunction with a data management program 190 
and frequent, rigorous outcome evaluation to determine whether the regimen is achieving the expected 191 
results. In some cases, such quality improvement programs produce generalizable knowledge and are 192 
appropriate subjects for research to improve care and save lives even beyond the local setting.  193 
One might argue that application of an adapted regimen that has not been validated by results 194 
from clinical trials represents a departure from standard care and therefore would constitute research. 195 
However, use of a regimen developed and studied only in HIC without adaptation for LMIC also 196 
represents a departure from standard care, since the context of treatment is different and limitations in 197 
supportive care and specific treatment modalities in LMIC can render a HIC regimen irrelevant or 198 
dangerous. In all cases, when treatment is provided with the goal to optimize the cure rate of an 199 
individual, consent for treatment should be obtained from the patient and family. By contrast, when 200 
information about outcomes is collected to produce generalizable knowledge with the intent to publish 201 
results, research committee approval should be obtained in advance, and the patient and family should 202 
provide consent for both treatment and participation in research. 203 
This framework document facilitates the adaptation process, standardizes terminology and levels 204 
of care, and assures that all necessary elements are included in each published adapted regimen. We hope 205 
that this will be followed by a proliferation of regimens adapted to various situations and prospectively 206 
validated in research studies. In this regard, the Wilms tumor regimen for Level 1 settings is being studied 207 
by a group of 8 centers in sub-Saharan Africa, which will show how the adapted regimen and its 208 
implementation can be further improved.32  209 
 210 
 211 
 212 
Standardized definitions of levels of care by service line 213 
Levels of care available at a PCU are defined by service lines for infrastructure and personnel 214 
(Table 2) needed to manage each pediatric cancer. Heterogeneity of services is common in LMIC, and 215 
service line levels are distinct from the regimen level selected for a particular cancer or patient: a PCU 216 
may have Level 0 radiation therapy (none) but may offer Level 3 chemotherapy and supportive care.  For 217 
the ALL regimen, such a PCU should choose the Level 3 treatment, but for Hodgkin lymphoma or Wilms 218 
tumor an adapted chemotherapy-only regimen is warranted.38,39  The selection of the initial treatment 219 
regimen for each disease should be based on levels of service relevant to the disease and available to the 220 
patient, not on the overall level of the PCU. Service levels for this framework paper were developed by a 221 
consensus of working group members in consultation with domain experts from HIC and LMIC (e.g. 222 
radiologists for radiology section, surgeons for surgery section). These represent a starting point for 223 
definition of service levels, which require significantly more nuanced and disease-specific definition and 224 
validation. For example, management of Hodgkin lymphoma generally does not require MRI, so one 225 
could consider availability of Level 3 diagnostic imaging services for Hodgkin lymphoma even if the 226 
center lacks access to MRI. However, for sarcomas, a hospital lacking MRI would be considered Level 2. 227 
Ultimately, we envision using this framework to help writing groups created service levels that are 228 
disease-specific and to some extent protocol-specific.  229 
Service levels outlined here are not primarily meant to be used to evaluate PCUs; rather, to help 230 
clinicians best choose the starting level for each disease (from which they will “step up” or “step down” 231 
as indicated by the stopping rules in each adapted regimen based on toxic death and relapse rates). 232 
Nuanced definition of service lines and application to adapted regimens for specific cancers will be 233 
carried out by global strategy groups like the World Health Organization, commissioned strategy groups 234 
like the Lancet Commissions, SIOP PODC Working Groups, regional networks, and others. 235 
 236 
Assessment of levels of care by service line and the importance of effective access 237 
This paper does not purport to offer a detailed guide to assessment and classification of PCUs; 238 
however, assessment of the level of each service line relevant for each cancer is a necessary first step to 239 
select the appropriate treatment regimens that will optimize outcomes. It must be emphasized that the 240 
level of each service line should reflect the level of service to which most patients have “effective 241 
access.”  The existence of services is irrelevant if the patient cannot access them due to overcrowding or 242 
inability to pay. A hospital with a Level 3 intensive care unit that is always full and therefore does not 243 
accept oncology patients is considered to have Level 0 intensive care, and the regimens adapted 244 
accordingly.  Using an intense regimen that requires intensive care is a mistake at this hospital, since 245 
effective access influences toxic death rates.  When determining the levels of service lines available, 246 
clinicians are encouraged to think in narrow terms: what services are effectively available to most patients 247 
most of the time? 248 
 Supportive care is important in the management of all pediatric cancers, but the level needed for 249 
acute myeloid leukemia (Level 3 for services including blood bank, intensive care, infection prevention 250 
and control) is higher than that needed for low-stage Wilms tumor (Level 0 or 1). Nutritional support is 251 
particularly important in LMIC, where malnutrition at diagnosis or during treatment is prevalent, and can 252 
increase the complication rate even for therapies that had minimal toxicity in HIC.40-43 The PODC 253 
Adapted Treatment Regimens Working Group Guidance for supportive care in LMIC has published 254 
guidance for LMIC, and many HIC guidelines are relevant for LMIC.28,44 All PCUs should have a 255 
multidisciplinary team, regardless of resource constraints. A team of doctors from multiple specialties, 256 
nurses, social workers, pharmacists, and data managers can accomplish most when working together. This 257 
core team can later mobilize other key professionals and community advocates needed for cancer care.  258 
 259 
Adapted regimen manuscript preparation, review, and publication 260 
Available infrastructure and personnel services at each “Level” should follow the standard 261 
descriptions provided herein and need not be repeated in future publications of SIOP PODC adapted 262 
treatment regimens. However, the disease- and regimen-specific requirements along with additional 263 
disease-specific services should be included in the adapted regimens for each disease (e.g. neurosurgery 264 
for brain cancer, ophthalmology for retinoblastoma, N-MYC testing for neuroblastoma). Authors should 265 
define the minimum requirements for each service line to deliver each proposed adapted regimen, 266 
including chemotherapy regimens, dosing levels and intervals, and radiation therapy suggested by level of 267 
care. Development of SIOP PODC adapted regimens occurs in collaboration with the Adapted Treatment 268 
Regimens Working Group, whose membership is open. A flow chart describes the process of 269 
development (Figure 1) and Figures 2 and 3 provide examples.  270 
Review by Working Group members and approval by group leaders is mandatory for all adapted 271 
regimens prior to submission to the SIOP Publications Committee to assure that all criteria are met and 272 
that the final product is clear and practical. Once approved, the manuscript may be submitted for 273 
additional peer review and publication. All manuscripts describing SIOP PODC adapted regimens should 274 
conform to the requirements enumerated in Table 3. Adapted regimens are designed with curative intent, 275 
even if conditions at the PCU suggest a regimen with a cure rate known to be less than that achievable in 276 
HIC. Use of the adapted regimen is ethically supported by the fact that alternative regimens, or lack 277 
thereof, would result in even lower cure rates. However, if a patient has access to a PCU with a higher 278 
cure rate for their disease, referral to that center is ethically mandatory. Furthermore, if patients have 279 
access to a locally adapted clinical trial this would be preferred over an adapted treatment regimen, which 280 
purports to describe the best standard therapy available for a given patient in a specific setting. However, 281 
awaiting the development and funding for such a clinical trial before implementing the best standard local 282 
care possible is not acceptable. Clinicians must attempt to choose the best treatment for each new patient 283 
each day, and adapted regimens are designed to facilitate this choice while awaiting better evidence (and 284 
better services within the PCU) to cure even more patients in the future. 285 
 286 
Adapted regimen dissemination, field testing, and updates 287 
The dissemination strategy has several components, including publication, presentation at SIOP 288 
Annual Meetings, regular open meetings of the SIOP PODC Adapted Treatment Regimen Working 289 
Group, education sessions via www.Cure4Kids.org, and creation of a repository of adapted regimens 290 
available via the SIOP web page and Cure4Kids. Extension of the concepts by Childhood Cancer 291 
International, consortia like GFAOP and AHOPCA, and groups like the Lancet Oncology Commission 292 
will provide further visibility. Getting the first set of adapted treatment regimens into the public sphere 293 
was the first priority of the SIOP PODC Adapted Treatment Regimen Working Group, because as 294 
Loblaw et al. point out: “…it is often the areas of greatest uncertainty in which the evidentiary base is 295 
incomplete, and thus, guidelines are needed most.”45 296 
  The initial group of adapted regimens were developed using a series of consensus meetings held via 297 
regular online meetings by disease-specific working groups with feedback from the larger Working 298 
Group that includes all members of the disease-specific working groups. After the first step (creation of 299 
the adapted regimen), the critical next steps include 1) prospective validation in a variety of centers that 300 
use the adapted regimen, 2) evaluation of practical implementation barriers, and 3) documentation of 301 
patient outcomes. This process is ongoing for acute lymphoblastic leukemia and Wilms tumor, and will 302 
be followed by revision of the adapted treatment regimen to address implementation barriers and modify 303 
the regimen as necessary based on results plus any new published relevant literature from HIC or LMIC. 304 
The Working Group should review each adapted treatment regimen annually and update it every 3 years. 305 
 306 
Selection of the optimal regimens for the Pediatric Cancer Unit 307 
The “optimal” treatment regimen depends on rates of treatment failure, toxic death, abandonment, 308 
second cancer, and the salvage rate for those who relapse. Ideally, treatment regimens best suited to each 309 
site would be established in collaboration with local clinicians, national, and international disease experts. 310 
The adapted regimen anticipated to cure the highest number of patients given the current status of the 311 
PCU should be used. It may be more intense, less intense, or simply different (such as using additional 312 
chemotherapy when radiation therapy is not available) than regimens used in HIC. 313 
Hodgkin lymphoma illustrates the nuances of “optimal” regimen selection. In HIC, the benefits of 314 
radiation therapy were documented in the short term (5-10 years) for various subgroups of patients. In the 315 
CCG5942 trial, patients with complete remission after chemotherapy were randomized to no further 316 
therapy or involved-field radiation therapy.46 At 10 years, EFS of children who received radiation therapy 317 
was 8% higher than with chemotherapy alone, but overall survival was similar.47 However, as late effects 318 
of radiation therapy occur longer than 10 years after treatment, in the long-term, omission of radiation 319 
therapy actually predicted better outcomes (in HIC). Indeed, a recently published decision analysis of 320 
patients treated in HIC found that average conditional life expectancy was higher without radiation 321 
therapy (57.2 years versus 56.4 years).48 However, this model does not apply in LMIC, where the rates of 322 
successful salvage therapy for those who relapse may be much lower than in HIC.49 In settings where 323 
salvage therapy is suboptimal, and few survivors are seen following relapse, a more intense front-line 324 
regimen may be preferred, and the benefits of radiation therapy may be greater than they were in HIC.  325 
Thorough evaluation of the level of each service line, combined with prospective analysis of 326 
outcomes for patients treated previously to document rates of abandonment, toxic death, relapse, and 327 
successful salvage allows selection of an appropriate approach for each cancer that will cure the greatest 328 
number of patients at each PCU. Service lines provide a framework for initial selection of the adapted 329 
regimen likely to have the highest cure rate in the specific setting, but the regimen may need adjustment 330 
based on outcome evaluation in case the initial selection was not optimal. Furthermore, regimens should 331 
be periodically evaluated and adjusted based on changing conditions: if the PCU improves access to 332 
intensive care for cancer patients, adds a guest house for patients who live far away, increases the number 333 
of nurses, or improves the speed with which antibiotics can be administered to patients with febrile 334 
neutropenia, then the best adapted regimen for some diseases may change. 335 
 336 
Individualized treatment for specific patients 337 
Individualized management of specific patients, whether on an adapted regimen or not, is inevitable in 338 
oncology.  Such individualized management depends on the experience of the treating clinician, ideally 339 
complemented by local multidisciplinary tumor boards and consultation with national or international 340 
disease experts. Although beyond the scope of this paper, the guiding principle for individualized 341 
management is to maximize the probability of cure for each individual patient. Conditions for a specific 342 
patient may warrant adjusting the regimen at the beginning for that individual to maximize her/his 343 
probability of cure. For example, in a pediatric cancer unit that uses a Level 1 regimen for childhood 344 
ALL, a patient with high risk of relapse due to adverse presenting leukemia features, who tolerated initial 345 
therapy in good condition, and who lives 100 meters from the PCU may be safely treated on a Level 2 or 346 
3 regimen. Such exceptions to the standard protocol used at the PCU should each be carefully justified 347 
and documented, and the regimens designed so that the treatment intensity can be increased without 348 
completely changing the backbone. Toxicities or other events that occur during therapy may warrant 349 
adjusting the regimen for an individual to maximize her/his probability of cure. Many PODC members 350 
participate in regular online meetings via www.Cure4Kids.org to discuss the management of individual 351 
patients and practical aspects of applying protocol-based care in diverse settings. Most such meetings are 352 
open, and there are several hundred per month in many regions, different languages, and for different 353 
diseases.50 No adapted regimen can substitute for the experience of the clinician and ready access to 354 
advice from expert colleagues. 355 
 356 
Conclusion 357 
Implementation of standardized care adapted to local conditions has the potential to improve outcomes 358 
and establish a global community using similar regimens in similar situations, thereby facilitating future 359 
treatment advances. Coupled with a data management program and continuous quality improvement, 360 
adapted regimens can produce the highest probability of cure for children with cancer in all settings. 361 
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 Table 1. Examples of strategies to development and implement adapted treatment regimens for children with cancer in low- and middle-
income countries 
Strategy Examples Mission Methods 
SIOP 
PODC 
Working 
Groups 
SIOP PODC Adapted 
Treatment Regimens 
Working Group 
Develop, adapt, implement, and 
improve treatment regimens for 
children with cancer in LMIC 
1. Regular online meetings (www.Cure4Kids.org) to develop adapted 
treatment regimens 
2. Implementation of adapted treatment regimens in LMIC with dissemination 
of results via SIOP presentations and peer-reviewed publications 
3. Improvement of regimens based on their utility and effectiveness 
Regional 
networks of 
peer 
pediatric 
oncology 
units 
AHOPCA 
GFAOP 
Improve care and outcomes for 
children with cancer and blood 
disorders in Central America 
(AHOPCA) and French-speaking 
African countries (GFAOP) 
1. Email contact to discuss patients, protocols, and supportive care issues 
2. Regular online meetings (www.Cure4Kids.org) to discuss patients, 
protocols, and supportive care issues 
3. Shared treatment regimens adapted to conditions of the PCUs in the 
regional network12,51-56 
4. Shared strategies to reduce treatment abandonment and toxic death 
5. Annual or bi-annual meetings to review all treatment regimens and discuss 
ways to further improve them 
6. Facilitated outcome evaluation, statistical analysis, and publication of 
results 
National 
networks of 
pediatric 
oncology 
units 
SOBOPE57  
GATLA58,59  
TPOG60 
InPOG61 
IPHOG62 
PINDA63 
Improve care and outcomes for 
children with cancer by 
implementing national protocols  
1. Shared protocols adapted to national conditions 
2. Shared strategies to address medication shortages and other national issues 
3. Annual meetings to review protocols and discuss ways to improve them 
4. Facilitated outcome evaluation, statistical analysis, and publication of 
results 
5. Educational exchange among participating PCUs 
Global 
disease-
specific 
networks 
Global Neuroblastoma 
Network 
Improve care and outcomes for 
children with neuroblastoma in 
LMIC and HIC 
1. Case discussion via online meetings (www.Cure4Kids.org)  
2. Development of adapted treatment regimens 
3. Facilitation of protocol design for PCUs in LMIC 
SIOP, International Society of Pediatric Oncology; PODC, Pediatric Oncology in Developing Countries committee of SIOP; LMIC, low- and 
middle-income countries; HIC, high-income countries; AHOPCA, Asociación Hemato-Oncología Pediátrica de Centroamérica; GFAOP, Groupe 
Franco-Africain d’Oncologie Pédiatrique; SOBOPE, Sociedade Brasileira de Oncologia Pediátrica; GATLA, Grupo Argentino de Tratamiento de 
la Leucemia Aguda; TPOG, Turkish Pediatric Oncology Group; InPOG, Indian Pediatric Oncology Group; INPHOG, Indian Pediatric 
Hematology-Oncology Group; PINDA, Programa Infantil Nacional de Drogas Antineoplásicas; PCU, pediatric cancer unit 
 Table 2. Characteristics of infrastructure and levels of each service line relevant for selection of SIOP PODC adapted treatment 
regimens* 
 
Service line Level 0 Level 1 Level 2 Level 3 Level 4 
General description 
Pediatric cancer 
unit general 
description* 
Pilot project Some basic oncology services Established pediatric oncology 
program with most basic 
services and a few state-of-
the-art services 
Pediatric oncology program with all 
essential services and most state-of-
the-art services 
Pediatric oncology center of 
excellence; state-of-the-art services 
and some highly-specialized 
services (e.g. proton beam radiation 
therapy, MIBG therapy, phase I 
studies) 
Typical settings Centers in LIC 
in 
disadvantaged 
areas 
Centers with relatively greater 
resources in LIC, disadvantaged 
areas in lower MIC 
Centers with relatively greater 
resources in lower MIC, 
disadvantaged centers in upper 
MIC 
Many centers in upper MIC, most 
centers in HIC 
Selected super-specialty centers that 
offer very advanced and high-
quality tertiary and quaternary care 
Medical facilities 
Inpatient ward 
No pediatric 
oncology 
inpatient unit 
Area of the hospital where 
children with cancer are admitted 
when possible; frequent overflow 
to other wards; no fixed staff 
Pediatric oncology inpatient 
ward available to most 
patients; limited fixed staff 
(e.g. oncology nurse 
permanently assigned) 
Pediatric oncology inpatient ward 
separate from inpatient units for 
other patients; sufficient beds such 
that oncology patients rarely require 
admission to other wards 
Subspecialized pediatric oncology 
wards (e.g. transplant, 
neurooncology, acute myeloid 
leukemia) 
Inpatient ward 
effective access 
Very limited 
access (e.g. 
due to lack of 
beds or high 
cost relative to 
typical 
family’s 
salary) 
Accessible to some patients 
sometimes 
Accessible to most patients 
most of the time 
Accessible to all patients almost 
always 
 
Isolation rooms 
for infected 
patients 
None 
Isolation rooms exist but rarely 
available 
Isolation rooms usually 
available when needed 
Isolation rooms almost always 
available when needed 
 
Outpatient 
facilities 
None 
Outpatient area for chemotherapy 
and some emergency care; 
services for surgery/diagnostic 
Outpatient area for 
chemotherapy and some 
emergency care available most 
Full-service outpatient care available 
24 hours/day for chemotherapy and 
emergencies; pediatric-specific 
Outpatient satellite facilities 
available to provide care close to 
home 
imaging may be primarily for 
adults but can partially 
accommodate pediatric patient 
needs 
of the time; services that can 
mostly accommodate pediatric 
patient needs for surgery and 
diagnostic imaging 
surgery and diagnostic imaging suites 
and services 
Outpatient 
facilities effective 
access 
Very limited 
access (e.g. 
due to lack of 
space or high 
cost relative to 
typical 
family’s 
salary) 
Accessible to some patients 
sometimes 
Accessible to most patients 
most of the time 
Accessible to all patients almost 
always 
 
Radiation therapy 
Radiation therapy 
facilities 
None Cobalt machine 
Linear accelerator or cobalt 
machine (cobalt machine is 
preferable in areas with poor 
electricity supply) 
Linear accelerator with fully 
integrated planning system 
Proton beam facility; advanced 
photon radiotherapy 
Radiation therapy 
planning tools 
None 2D planning 
Some 3D planning available to 
some patients 
3D planning, full conformal therapy 
available; intensity-modulated and 
volumetric modulated arc therapy 
(VMAT) available to some patients 
All specialized techniques available, 
including proton beam, 
radiosurgery, and VMAT 
Radiation 
therapists 
None 
Radiation oncologists with adult 
expertise 
Radiation oncologists with 
some pediatric experience 
Radiation oncologists with pediatric 
expertise 
Pediatric radiation oncologists with 
highly specialized disease-specific 
expertise 
Anesthesia for 
radiation therapy 
None Sedation only 
Sedation/anesthesia from 
general anesthesiologists 
available for some pediatric 
patients 
Sedation/anesthesia from pediatric 
anesthesiologists available for most 
pediatric patients 
Experienced pediatric 
anesthesiologists routinely available 
for all pediatric patients requiring 
radiation therapy 
Radiation therapy 
personnel 
(medical 
physicists, 
radiation therapy 
technicians) 
None 
Few personnel, no pediatric 
expertise 
Adequate personnel with some 
pediatric expertise 
Adequate personnel with experience 
using advanced techniques and with 
pediatric expertise 
Subspecialty expertise in specific 
pediatric cancer types (e.g. brain 
cancers) 
Radiation therapy 
effective access 
None 
Radiation therapy available to 
some patients some of the time; 
frequent delays 
Conformal radiation therapy 
available to most patients most 
of the time; occasional delays 
Modern radiation therapy options 
reliably available to all patients in a 
timely way 
Full range of radiation therapy 
options available to all patients 
Access to medications 
Antineoplastic 
drug availability 
Very limited 
access to a 
small selection 
of oncology 
drugs 
Access to a limited selection of 
oncology drugs; frequent 
shortages 
Access to most essential 
oncology drugs; occasional 
shortages 
Access to almost all commercially 
available drugs; rare shortages 
Access to all approved drugs, plus 
phase I and phase II studies 
Antineoplastic 
drug quality 
Low or 
unknown 
quality 
Variable or unknown quality 
Occasional access to high-
quality branded medicines; 
generic medicines of mostly 
good quality 
Consistent access to high-quality 
branded and generic medicines 
 
Antineoplastic 
drug effective 
access 
Dependent 
entirely on 
NGO support 
or out-of-
pocket 
payment 
Limited supply of basic drugs 
accessible from the health system; 
dependent on NGO support or 
out-of-pocket payment for some 
drugs much of the time or most 
drugs some of the time 
Basic drugs provided by the 
health system, more expensive 
drugs may depend on private 
insurance or NGO support 
Most oncology drugs provided by the 
health system or private insurance 
available to most patients 
Full access to all drugs by all 
patients 
Antimicrobial 
drug availability 
Limited 
selection, 
delayed access 
Limited selection available to 
most patients, some delays 
Wide selection available to 
most patients with minimal 
delays, some antifungals 
available 
Wide selection of antibiotics, 
antifungal agents, and antiviral 
agents available to all patients with 
rare delays 
Access to compassionate use 
(single-patient exceptions for 
unapproved medicines) and 
protocols for new antimicrobials 
Antimicrobial 
drug effective 
access 
Dependent 
entirely on 
NGO support 
or out-of-
pocket 
payment 
Limited supply of basic drugs 
from the health system; 
dependent on NGO support for 
some drugs much of the time or 
most drugs some of the time 
Basic drugs provided by the 
health system, more expensive 
drugs may depend on private 
insurance or NGO support 
Most antimicrobial drugs provided 
by the health system or private 
insurance available to most patients 
Full access to all drugs by all 
patients 
Analgesic drug 
availability 
Limited 
selection of 
analgesics, 
delayed access 
Limited selection of opioid and 
non-opioid analgesics available to 
most patients, some delays 
Moderate selection of opioid 
and non-opioid analgesics 
available to most patients with 
minimal delays 
Wide selection of analgesic agents, 
access to multiple pain management 
modalities (e.g. nerve block); pain 
management specialists available 
when needed 
Wide range of enteral and parenteral 
opioid and non-opioid analgesics; 
full spectrum of pain management 
modalities; pain management 
specialists embedded in the 
multidisciplinary team 
Analgesic 
effective access 
Dependent 
entirely on 
NGO support 
or out-of-
pocket 
payment; 
significant 
regulatory or 
Limited supply of basic drugs 
from the health system; 
dependent on NGO support or 
out-of-pocket payment for much 
of the time; some regulatory and 
cultural barriers 
Basic drugs provided by the 
health system, more expensive 
drugs may depend on private 
insurance or NGO support; 
few regulatory or cultural 
barriers 
Most drugs provided by the health 
system or private insurance available 
to most patients; no regulatory or 
cultural barriers 
Full access by all patients with no 
delays  
cultural 
barriers 
Supportive care 
drug availability 
(e.g. anti-emetics, 
constipation 
management, 
growth factors) 
Limited 
selection, 
delayed access 
Limited selection available to 
most patients, some delays 
Wide selection available to 
most patients with minimal 
delays 
Wide selection of anti-emetics, 
growth factors, and other supportive 
care medicines available to all 
patients with rare delays 
Access to compassionate use 
protocols for new and experimental 
supportive care medicines 
Supportive care 
drug effective 
access 
Dependent 
entirely on 
NGO support 
or out-of-
pocket 
payment 
Limited supply of basic drugs 
from the health system; 
dependent on NGO support or 
out-of-pocket payment for some 
drugs much of the time or most 
drugs some of the time 
Basic drugs provided by the 
health system, more expensive 
drugs may depend on private 
insurance or NGO support 
Most oncology drugs provided by the 
health system or private insurance 
available to most patients 
Full access to all drugs by all 
patients 
Supportive care 
Blood product 
availability 
Whole blood  
Some blood products available 
sometimes for some patients; no 
irradiation/filtration possible 
Red blood cells, platelets, 
cryoprecipitate, and fresh 
frozen plasma often available; 
irradiated/filtered blood 
products sometimes available  
Ready availability of all blood 
products, including pheresed platelet 
units; routine access to 
irradiated/filtered blood products  
 
Blood product 
effective access 
Accessible to a 
few patients; 
long and 
frequent 
delays 
Accessible sometimes for some 
patients; frequent delays 
Usually accessible to most 
patients within a reasonable 
time period 
Accessible to all patients within 2 
hours 
 
Intensive care 
availability 
None 
Intensive care unit present; 
limited equipment; personnel with 
limited pediatric experience 
Mechanical ventilators, 
inotropes, central venous 
access, dialysis; personnel 
with some pediatric expertise 
Pediatric intensive care unit with all 
necessary equipment and personnel 
with pediatric intensive care 
expertise 
Advanced cardiopulmonary support 
available (extracorporeal membrane 
oxygenation) 
Intensive care 
effective access 
Not accessible 
to most 
patients 
Accessible to some oncology 
patients occasionally; frequently 
delayed access 
Accessible to some oncology 
patients when space available; 
occasionally delayed access 
Readily accessible to all patients  
Infection 
prevention and 
control  
None 
Hand hygiene stations usually 
available; prophylactic antibiotics 
for Pneumocystis jiroveci usually 
available 
Hand hygiene widely 
practiced; prophylactic 
antibiotics for Pneumocystis 
jiroveci always available 
Universal hand hygiene, adequate 
positive and negative pressure 
isolation rooms 
 
Nutritional 
support 
availability and 
effective access6 
None 
Limited nutritional support 
available to some patients; staff 
with limited training or 
experience in management of 
nutritional issues 
Enteral feeding always 
available and parenteral 
feeding available sometimes; 
some staff with nutrition 
training or experience 
Enteral and parenteral feeding 
(including individualized 
preparations) always available; 
trained pediatric nutritionists 
available to all patients 
Full access to a wide array of 
specialized nutritional support 
modalities by trained pediatric 
oncology subspecialist staff 
Venous access 
Peripheral IV 
access 
Mainly Peripheral IV access; 
PICC available to some patients 
Central venous access and a 
care plan for patients with a 
central line available to 
selected patients 
Central venous access and a care plan 
for patients with a central line 
available to all patients 
 
Safe 
chemotherapy 
preparation 
infrastructure 
None 
No special chemotherapy 
preparation area; no access to 
personal protective equipment 
Ventilated chemotherapy 
preparation area (e.g. to 
outside); access to personal 
protective equipment usually 
available 
Chemotherapy preparation hood 
available; access to personal 
protective equipment always 
available 
 
Pain and symptom 
management team 
No specific 
program 
Pain and symptom management 
by oncology personnel without 
special expertise in this area 
Some specialized pain and 
symptom management 
personnel; some pediatric 
experience 
Specialized pain and symptom 
management personnel; pediatric 
expertise 
Service with a full range of 
pharmacologic and non-
pharmacologic tools for pain and 
symptom management tailored for 
children  
Diagnosis and staging 
General 
laboratory 
availability 
Must send out 
even basic labs 
Blood chemistry profile and 
hemogram 
Blood chemistry profile and 
hemogram, plus some 
specialized testing (e.g. 
ferritin, urine catecholamines); 
rapid turnaround time possible 
for critical labs 
Blood chemistry profile and 
hemogram, wide range of specialized 
testing (e.g. methotrexate levels, 
fractionated plasma/urine 
metanephrines); rapid turnaround 
time routine for critical labs 
Reference laboratory including 
specialized testing for 
pharmacokinetics, phase 1 studies, 
etc. 
General 
laboratory 
effective access 
Rarely 
accessible, 
depends on 
NGO support 
Accessible to some patients 
sometimes; may depend on 
financial situation or NGO 
support 
Accessible to most patients; 
partial dependence on 
financial situation or NGO 
support 
Accessible to all patients with rare 
exceptions; 24-hour service 7 days 
per week and holidays 
 
Pathology 
availability 
None 
Microscope, H&E staining, CSF 
cytology 
Limited immunohisto-
chemistry panel (disease-
specific), cytospin for CSF 
samples 
Complete immunohisto-chemistry 
panel; molecular pathology and 
cytogenetics for most diseases; 
pediatric expertise necessary for 
specific diagnosis and staging; access 
to consultation with disease-specific 
expert pathologists at other centers 
Research diagnostics, whole 
genome sequencing, molecular 
pathology for all diseases 
Pathology 
effective access 
Rarely 
accessible; 
depends on 
NGO support; 
long delays 
Accessible to some patients 
sometimes; may depend on 
financial situation or NGO 
support; frequent delays in access 
to results 
Accessible to most patients; 
partial dependence on 
financial situation or NGO 
support; occasional delays in 
access to results 
Accessible to all patients with rare 
exceptions; rare delays in access to 
results 
 
Pathology 
personnel 
No pathologist 
Pathologist available for some 
cases 
Pathologist available for all 
cases 
Pediatric pathologist available for all 
cases 
Pathologist with highly specialized 
disease-specific expertise  
Hematopathology 
availability 
None 
Microscope, H&E staining, CSF 
cytology 
Limited immunohisto-
chemistry panel (disease-
specific), flow cytometry and 
cytogenetics available most of 
the time 
Flow cytometry of high quality; 
minimal residual disease testing; 
molecular pathology and 
cytogenetics; pediatric expertise; 
access to consultation with disease-
specific expert pathologists at other 
centers 
Research diagnostics, whole 
genome sequencing, molecular 
pathology for all diseases 
Hematopathology 
effective access 
Rarely 
accessible, 
depends on 
NGO support 
Accessible to some patients 
sometimes; may depend on 
financial situation or NGO 
support 
Accessible to most patients; 
partial dependence on 
financial situation or NGO 
support 
Accessible to all patients with rare 
exceptions 
 
Hematopathology 
personnel 
No hemato-
pathologist 
Hematopathologist available for 
some cases; hematologist with 
some hematopathology expertise 
Hematopathologist available 
for most cases; oncologist 
with extensive pediatric 
hematopathology expertise 
Hematopathologist with pediatric 
expertise available for all cases 
Hematopathologist with highly 
specialized disease-specific 
expertise  
Diagnostic 
imaging 
availability 
None Radiographs, ultrasound 
CT scan, bone scintigraphy, 
gallium scintigraphy; 
occasional availability of 
anesthesia when needed 
Magnetic resonance imaging PET-
CT available to most patients; routine 
availability of anesthesia when 
needed 
Specialized imaging; advanced 
nuclear medicine applications (e.g. 
metaiodobenzylguanidine [MIBG] 
scanning) 
Diagnostic 
imaging effective 
access 
Rarely 
accessible, 
depends on 
NGO support 
Accessible to some patients 
sometimes; may depend on 
financial situation or NGO 
support 
Accessible to most patients; 
partial dependence on 
financial situation or NGO 
support 
Accessible to all patients with rare 
exceptions 
 
Diagnostic 
imaging personnel 
No radiologist 
Radiologist available to interpret 
most imaging, occasional delays 
Radiologist available to 
interpret all imaging in real 
time; some interventional 
radiology 
Pediatric radiologist available to 
interpret all imaging in real time; 
advanced interventional radiology 
Pediatric radiologist with highly 
specialized disease-specific 
expertise 
Personnel not included with specific service lines above 
Multidisciplinary 
team 
Absent Ad hoc meetings for special cases 
Routinely scheduled meetings 
with reasonable attendance 
Real-time discussion of all complex 
cases to guide important care 
decisions 
Incorporation of molecular and 
genetic expertise in meetings; 
cancer-specific multi-disciplinary 
meetings like a CNS tumor or a 
sarcoma meeting. 
Oncology team 
leader  
Primary care 
physicians 
care for cancer 
and many 
other diseases 
Primary care provider with 
interest in oncology 
Primary care provider with 
pediatric oncology experience 
or some training, medical 
oncologist without pediatric 
expertise 
Pediatric oncologist or medical 
oncologist with significant pediatric 
experience or training 
Pediatric oncologist with highly 
disease-specific expertise 
Oncology team 
training and 
experience 
A few staff 
members with 
basic training  
A few oncology personnel with 
some oncology training; trainees 
responsible for many aspects of 
patient care 
Generally adequate numbers 
of oncology personnel; 
consistent supervision of any 
trainees involved in patient 
care 
Full complement of pediatric 
oncologists; specialized oncology 
nurses; pharmacists with oncology 
training 
Full complement of oncology 
personnel, including specialized 
physician extenders (e.g. nurse 
practitioners, hospitalists) 
Oncology 
physician 
effective access 
Rarely 
accessible; for 
private 
patients only 
Occasionally accessible; most 
oncology work done by non-
oncologists 
Usually accessible, some 
oncology work done by non-
oncologists or medical 
oncologists with some 
pediatric expertise 
All patients cared for by pediatric 
oncologists 
 
Nurse training and 
expertise 
No nurses with 
oncology 
training and no 
experience 
with oncology 
patients 
Nurses with no specialized 
oncology training; some 
experience with cancer patients 
Nurses with some dedicated 
oncology training and 
experience (e.g. the ability to 
handle chemotherapy); 
oncology nurses not 
permanently assigned to the 
oncology unit; nurse educator 
available sometimes 
Nurses with oncology training and 
experience who are permanently 
assigned to the pediatric cancer unit; 
nurse educators available 
Highly specialized pediatric cancer 
nurses with disease-specific 
expertise 
Nursing effective 
access 
Extremely low 
nurse-to-
patient ratio 
for oncology 
patients (1:25 
or lower) 
Very low nurse-to-patient ratio 
for oncology patients (1:15 or 
lower) 
Low nurse-to-patient ratio for 
oncology patients (1:7 or 
lower) 
Adequate nurse-to-patient ratio for 
oncology patients (1:6 or higher) 
 
Surgery  No surgeon 
General surgeon; limited pediatric 
experience 
Pediatric surgeon with limited 
oncology experience, 
oncology surgeon with limited 
pediatric experience 
Pediatric oncology surgeon 
Pediatric cancer surgeons with 
highly specialized disease-specific 
expertise 
Surgical 
subspecialties 
relevant for 
oncology 
None 
Adult subspecialty surgeon 
(neurosurgeon, orthopedic 
surgeon, ophthalmologist, other) 
Some pediatric subspecialty 
surgeons (neurosurgeon, 
orthopedic surgeon, 
ophthalmologist, other) 
Full range of pediatric subspecialty 
surgeons (neurosurgeon, orthopedic 
surgeon, ophthalmologist, other) 
Pediatric subspecialty surgeons with 
highly specialized disease-specific 
expertise 
Anesthesiologists  None 
Anesthesiologist available 
sometimes 
Anesthesiologists available for 
major procedures 
Pediatric anesthesiologists available 
for all procedures; cancer surgery 
experience 
Pediatric anesthesiologist with 
highly specialized disease-specific 
expertise 
Pharmacists  None 
Pharmacist in the hospital to 
dispense medications, but not 
available to prepare 
chemotherapy  
Pharmacist available to 
prepare most chemotherapy 
and provide support to doctors 
and nurses  
Dedicated oncology pharmacist with 
expertise preparing chemotherapy 
and monitoring drug safety 
Highly specialized pediatric 
oncology pharmacists with expertise 
with specific patient groups (e.g. 
transplant) and medicine classes 
Infectious disease 
specialists 
None 
General pediatricians manage 
infectious disease problems  
Pediatricians with special 
interest in infectious disease 
available for some patients 
Pediatric infectious disease 
subspecialist available for most 
patients  
Pediatric infectious disease 
subspecialist embedded in the 
multidisciplinary oncology team 
Pediatric 
subspecialty 
support (e.g. 
nephrology, 
neurology, 
endocrinology) 
None 
General pediatricians manage 
subspecialty problems 
Pediatricians with a special 
interest in subspecialty care 
Pediatric subspecialists in most 
specialties 
Pediatric subspecialists in all 
specialties 
Professions allied 
to medicine (e.g. 
physical therapist, 
occupational 
therapist, speech 
therapist, 
psychologist) 
None 
Some availability of some 
professionals 
Some availability of most 
professionals for most patients 
Full range of allied healthcare 
professions available 
Professionals with specialized, 
pediatric, disease-specific expertise 
Social workers None 
Small number of social workers 
available to some patients 
Social workers available to 
most patients 
Adequate number and training of 
social workers available to all 
patients 
Professionals with specialized 
pediatric, disease-specific expertise 
Logistical and social support 
Abandonment 
prevention 
program 
None 
Limited support for some 
patients’ non-medical expenses. 
Limited support for some medical 
expenses. Limited access to 
psychologists, social workers, and 
parent support groups. 
Guest house, subsidized food 
and subsidized transportation 
for some patients some of the 
time. Substantial support for 
most medical expenses for 
most patients. Some access to 
psychologists, social workers, 
and parent support groups. 
Guest house, subsidized food and 
subsidized transportation provided to 
all patients with documented need. 
Full support for almost all medical 
expenses for almost all patients. 
Reliable access to psychologists, 
social workers, and parent support 
groups for all patients. 
Full support for housing, food, 
transportation, and daily non-
medical necessities. Vocational 
training and support for school for 
patients and families. Full support 
for all medical expenses for all 
patients. Universal access to 
psychologists, social workers, and 
parent support groups for all 
patients. 
Guest house 
(patient/family 
lodging) 
None 
Available to a few patients; 
delayed access; over-crowded 
Available to many patients; 
occasional overcrowding 
Adequate number of rooms, rapid 
and easy access to the hospital or 
outpatient care 
 
Appointment 
scheduling and 
call-back system 
None 
Appointment records kept, no 
systematic way to identify 
patients who miss an appointment 
System to identify patients 
who miss appointments; ad 
hoc tracking and call-back 
Electronic appointment system with 
automated warnings for missed 
appointments; tracking system to 
contact patients who miss 
appointments 
Electronic appointment and tracking 
systems fully integrated into a state-
of-the art electronic health record 
Transportation 
support 
None 
Some transportation subsidy for 
some patients 
Transportation subsidy for 
most patients who need it 
Full transportation subsidy and 
tracking to proactively identify 
patient needs 
 
Patient and family 
education 
None 
Some education for some patients 
and families 
System for patient and family 
education for most patients 
Routine and continuous patient and 
family education for all patients 
 
Patient and family 
support groups 
None 
Ad hoc support by some families 
of others; not supported by the 
oncology service 
Support groups that meet 
regularly; support from the 
oncology service 
Routine and integrated patient and 
family support groups fully 
supported and moderated by trained 
pediatric oncology personnel (e.g. 
psychologist, social worker) 
 
Health system 
Satellite centers 
for shared care 
None 
Informal relationship with local 
primary care colleagues. 
Communication delayed or 
sporadic. 
Network of primary care 
colleagues willing to facilitate 
some aspects of treatment and 
follow-up. Communication as 
needed for specific patients 
Network of primary, secondary, and 
tertiary care centers with established 
communication methods and written 
procedures for the care that should be 
provided at each center. 
 Advanced, integrated referral and 
communication pathways and fully 
shared medical records 
Data management 
program 
None 
Record of patients treated is kept 
ad hoc by various staff members 
Data manager collects basic 
information about most 
patients. Electronic database 
with occasional back-ups. 
Data manager collects basic 
information about all patients and 
detailed information for those treated 
with specific regimens. Regular 
evaluation of outcomes, including 
toxic death, abandonment, and event-
free survival. Electronic database 
with daily back-up procedure, access 
controls, and security procedures. 
Data manager career ladders fully 
implemented and local team capable 
of advanced data analysis to guide 
care. Database fully integrated with 
the electronic health record. 
Research focused 
on quality 
improvement and 
enhancing clinical 
care 
None 
Limited single-center research 
including retrospective analyses 
with limited outcome data 
Single-center retrospective 
studies with good follow-up 
and outcome data, prospective 
studies 
Multi-center retrospective or 
prospective observational studies or 
those with single arm interventions; 
benchmarking against other hospitals 
to identify areas for improvement 
Part of prospective multi-center 
Phase III randomized controlled 
trials; Phase I/II trials; contributing 
to generalized knowledge locally, 
regionally, nationally, and 
internationally 
* These categories are provided to facilitate initial selection of the appropriate SIOP PODC adapted treatment regimen for each type of cancer, not 
primarily as an evaluation tool for PCUs. PCU, pediatric cancer unit; PICC, peripherally inserted central line, PODC, Pediatric Oncology in 
Developed Countries; CSF, Cerebrospinal fluid; CT, computed tomography; H&E, Hemotoxylin and Eosin; NGO, non-governmental 
organization; LIC, low-income country; MIC, middle-income country; HIC, high-income country; MIBG, metaiodobenzylguanidine 
 
 
Table 3. Requirements for SIOP PODC adapted regimen publications 
 
Component Requirement 
Service lines and levels Use the service lines and levels outlined in this guidance paper (Table 2).  
The writing committee for each adapted regimen is expected to elaborate where necessary. 
Diagnosis and risk 
stratification 
Specify the approach to the disease-specific elements needed for adapted diagnosis, staging, and risk stratification 
Include a flow chart with a clear algorithm to guide application of the adapted diagnosis, staging, and risk stratification to arrive at the 
correct adapted treatment regimen (see the example in Figure 3). 
Treatment regimens Identify the levels of each service line needed for each level of the adapted regimen (see the example in Figure 2). 
Specify adapted treatment regimens and response evaluation in a table with details sufficient to treat the patient (number of cycles, 
criteria to start each cycle, required and recommended monitoring, dose modification recommendations for toxicities, timing of local 
control when relevant, timing of response evaluation, response criteria). 
Include alternatives with similar efficacy where they exist (e.g. ABVD vs. OEPA/COPDac for Hodgkin lymphoma). 
Outline key management differences for initial regimen selection and any alteration in timing of surgery or chemotherapy as mandated 
by local surgical or patient factors (e.g. upfront surgery vs. chemotherapy for retinoblastoma or Wilms tumor). 
Provide detailed recommendations and rationale to guide potential decision-making for chemotherapy substitution or regimen 
readjustments when individual chemotherapeutic agents are missing. 
Provide treatment roadmaps that include all elements of treatment for all phases of the regimen (drugs, doses, route of administration, 
fluid in which to mix the chemotherapy, schedule, recommended evaluations, timing of local control). 
Explicitly recommend strategies to treat patients when key elements are missing (e.g. lack of radiation therapy, laser therapy for local 
control of retinoblastoma, or access to stem cell transplantation). 
Make the adapted regimens as evidence-based as possible and provide supporting references.  
Evidenced-based 
recommendations 
Note the level of evidence available for specific recommendations, and outline to the extent possible the practice settings where 
evidence has been primarily generated. 
Supportive care  Provide supportive care recommendations that address common toxicities of the proposed regimens and any unique complications of 
the cancer. 
No need to provide general recommendations, which are available from various sources.23 
Diagnostic evaluation 
and monitoring 
Consider any data that may support less intense diagnostic evaluation or monitoring. 
Consider evidence that justifies allocation of resources for specific testing. 
Selection of the most 
appropriate initial 
regimen for a particular 
pediatric cancer unit 
Provide guidance to help clinicians identify the optimal regimen for their patients given the available resources.   
Include stopping rules for toxic death when one should “step down” to a less intense regiment. 
Provide criteria to “step up” to the next regimen and specific guidance about when and how to step up or step down to a different 
regimen to cure the highest number of children possible. 
Review process Follow the approval process that includes review by the SIOP PODC Adapted Treatment Regimens Working Group leaders and by the 
SIOP Publications Committee prior to submission for publication (See Figure 1) 
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